Company intelligence / Profile preview
Migralex
- Ownership
- Private
- Development stage
- Other
Overview
Migralex is a specialty pharmaceutical company focused on the development and commercialization of over-the-counter treatments for migraine and tension-type headaches. The company's flagship product, Migralex, is a unique formulation that combines aspirin with magnesium oxide to facilitate rapid absorption and reduce gastrointestinal irritation. Founded by Dr. Alexander Mauskop, a renowned neurologist and director of the New York Headache Center, the company aims to provide patients with a fast-acting alternative to traditional oral pain relievers. Migralex is designed to offer the potency of prescription-level relief in an accessible, non-prescription format, specifically targeting the physiological mechanisms of acute migraine attacks.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Migralex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Migralex.